연구업적

연도	2024년	2023년	2022년	2021년	2020년
SCI 논문 발표편수	책임	179편	173편	163편	184편	135편
공동	147편	120편	115편	136편	168편
합계	326편	293편	278편	320편	303편

3477. Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer

Park C, Suh KJ, Kim SH, Lee KH, Im SA, Kim MH, Sohn J, Jeong JH, Jung KH, Lee KE, Park YH, Kim HJ, Cho EK, Choi IS, Noh SJ, Shin I, Cho DY, Kim JH

Cancer immunology, immunotherapy : CII 2024 Aug 6;73(10):197. Link

3476. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study

Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Han W, Im SA, Tan VKM, Phyu N, Wong FY, Tan PH, Yap YS

Journal of the National Comprehensive Cancer Network : JNCCN 2024 May 14;22(2D):e237121. Link

3475. An Antibody-CRISPR/Cas Conjugate Platform for Target-Specific Delivery and Gene Editing in Cancer

Yang S, Im SH, Chung JY, Lee J, Lee KH, Kang YK, Chung HJ.

Adv Sci (Weinh). 2024 Jun;11(21):e2308763. Link

3474. Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy

Dongchan Kim, Sheehyun Kim, Hyojin Song, Daehyeon Gwak, Suji Min, Ja Min Byun, Youngil Koh, Junshik Hong, Sung-Soo Yoon, Hongseok Yun, Dong-Yeop Shin

Cancer Med. 2024 Apr;13(7):e7182 Link

3473. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Ana Oaknin 1, Jung-Yun Lee 2, Vicky Makker 3 4, Do-Youn Oh 5 6 7, Susana Banerjee 8 9, Antonio González-Martín 10, Kyung Hae Jung 11, Iwona Ługowska 12, Luis Manso 13, Aránzazu Manzano 14, Bohuslav Melichar 15, Salvatore Siena 16 17, Daniil Stroyakovskiy 18, Anitra Fielding 19, Soham Puvvada 19, Ann Smith 20, Funda Meric-Bernstam 21

Adv Ther. 2024 Nov;41(11):4125-4139 Link

3472. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Narikazu Boku 1, Takeshi Omori 2, Kohei Shitara 3, Shinichi Sakuramoto 4, Kensei Yamaguchi 5, Ken Kato 6, Shigenori Kadowaki 7, Kunihiro Tsuji 8, Min-Hee Ryu 9, Do-Youn Oh 10, Sang Cheul Oh 11, Sun Young Rha 12, Keun-Wook Lee 13, Ik-Joo Chung 14, Sun Jin Sym 15, Li-Tzong Chen 16 17, Jen-Shi Chen 18, Li-Yuan Bai 19, Takashi Nakada 20, Shunsuke Hagihara 21, Reina Makino 22, Eiji Nishiyama 22, Yoon-Koo Kang 23

Gastric Cancer. 2024 Nov;27(6):1287-1301. Link

3471. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX

Min Kyu Kim 1, In Rae Cho 2, Yooeun Kim 3, Jin Ho Choi 2, Kwangrok Jung 4, Jaihwan Kim 4, Sheehyun Kim 5, Hongseok Yun 5, Jeesun Yoon 6, Do-Youn Oh 6, Kwangsoo Kim 7, Sang Hyub Lee 8

Ther Adv Med Oncol. 2024 Oct 23:16:17588359241290482. Link

3470. Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial

Petros Grivas 1, Elena Garralda 2, Funda Meric-Bernstam 3, Ingo K Mellinghoff 4, Lipika Goyal 5, James J Harding 6 7, E Claire Dees 8, Rastislav Bahleda 9, Nilofer S Azad 10, Asha Karippot 11, Razelle Kurzrock 12, Josep Tabernero 2, Juha Kononen 13, Matthew C H Ng 14, Rutika Mehta 15, Nataliya V Uboha 16, Frédéric Bigot 17, Valentina Boni 18, Samantha E Bowyer 19, Valeriy Breder 20, Andrés Cervantes 21 22, Nancy Chan 23, James M Cleary 24, Mallika Dhawan 25, Rikke L Eefsen 26, James Ewing 27, Do

Clin Cancer Res. 2024 Oct 15;30(20):4572-4583. Link

3469. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

James J Harding 1, Jia Fan 2, Do-Youn Oh 3, Hye Jin Choi 4, Jin Won Kim 5, Heung-Moon Chang 6, Lequn Bao 7, Hui-Chuan Sun 2, Teresa Macarulla 8, Feng Xie 9, Jean-Phillippe Metges 10, Jie'er Ying 11, John Bridgewater 12, Myung-Ah Lee 13, Mohamedtaki A Tejani 14, Emerson Y Chen 15, Dong Uk Kim 16, Harpreet Wasan 17, Michel Ducreux 18, Yuanyuan Bao 19, Stacie Lindsey 20, Melinda Bachini 20, Helen Morement 21, Lisa Boyken 22, Jiafang Ma 19, Phillip Garfin 23, Shubham Pant 24; HERIZON-BTC-01 study gr

Future Oncol. 2024;20(31):2319-2329. Link

3468. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh 1, Daniel Halperin 2, Sten Myrehaug 3, Ken Herrmann 4, Marianne Pavel 5, Pamela L Kunz 6, Beth Chasen 2, Salvatore Tafuto 7, Secondo Lastoria 8, Jaume Capdevila 9, Amparo García-Burillo 9, Do-Youn Oh 10, Changhoon Yoo 11, Thorvardur R Halfdanarson 12, Stephen Falk 13, Ilya Folitar 14, Yufen Zhang 15, Paola Aimone 14, Wouter W de Herder 16, Diego Ferone 17; all the NETTER-2 Trial Investigators

Lancet. 2024 Jun 29;403(10446):2807-2817. Link

최근 5년 연구업적 현황